Vincenzo Stanghellini

List of Publications by Year
in descending order

149 papers	13,209 citations	34016 52 h-index	22764 112 g-index
153 all docs	153 docs citations	153 times ranked	8717 citing authors

#	Article	IF	Citations
1	Functional Gastroduodenal Disorders. Gastroenterology, 2006, 130, 1466-1479.	0.6	1,740
2	Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology, 2004, 126, 693-702.	0.6	1,246
3	Gastroduodenal Disorders. Gastroenterology, 2016, 150, 1380-1392.	0.6	1,088
4	Mast Cell-Dependent Excitation of Visceral-Nociceptive Sensory Neurons in Irritable Bowel Syndrome. Gastroenterology, 2007, 132, 26-37.	0.6	668
5	Assessment of gastric emptying using a low fat meal: establishment of international control values. American Journal of Gastroenterology, 2000, 95, 1456-1462.	0.2	611
6	Prevalence and Socioeconomic Impact of Upper Gastrointestinal Disorders in the United States: Results of the US Upper Gastrointestinal Study. Clinical Gastroenterology and Hepatology, 2005, 3, 543-552.	2.4	339
7	Manometric Evaluation of Functional Upper Gut Symptoms. Gastroenterology, 1985, 88, 1223-1231.	0.6	338
8	Gastroparesis Cardinal Symptom Index (GCSI): Development and validation of a patient reported assessment of severity of gastroparesis symptoms. Quality of Life Research, 2004, 13, 833-844.	1.5	311
9	Interactions Between Commensal Bacteria and Gut Sensorimotor Function in Health and Disease. American Journal of Gastroenterology, 2005, 100, 2560-2568.	0.2	291
10	Inflammatory neuropathies of the enteric nervous systemâ˜†. Gastroenterology, 2004, 126, 1872-1883.	0.6	265
11	Gastroparesis. Nature Reviews Disease Primers, 2018, 4, 41.	18.1	235
12	Chronic intestinal pseudo-obstruction. World Journal of Gastroenterology, 2008, 14, 2953.	1.4	195
13	Fat-induced heal brake in humans: A dose-dependent phenomenon correlated to the plasma levels of peptide YY. Gastroenterology, 1993, 105, 733-739.	0.6	187
14	Intestinal Serotonin Release, Sensory Neuron Activation, and Abdominal Pain in Irritable Bowel Syndrome. American Journal of Gastroenterology, 2011, 106, 1290-1298.	0.2	179
15	Natural History of Chronic Idiopathic Intestinal Pseudo-Obstruction in Adults: A Single Center Study. Clinical Gastroenterology and Hepatology, 2005, 3, 449-458.	2.4	176
16	The Immune System in Irritable Bowel Syndrome. Journal of Neurogastroenterology and Motility, 2011, 17, 349-359.	0.8	171
17	Chronic intestinal pseudo-obstruction: manifestations, natural history and management. Neurogastroenterology and Motility, 2007, 19, 440-452.	1.6	158
18	Current management strategies and emerging treatments for functional dyspepsia. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 187-194.	8.2	155

#	Article	IF	Citations
19	Gastroparesis: a turning point in understanding and treatment. Gut, 2019, 68, 2238-2250.	6.1	144
20	Gastroparesis: separate entity or just a part of dyspepsia?. Gut, 2014, 63, 1972-1978.	6.1	128
21	Nerve Fiber Outgrowth Is Increased in the Intestinal Mucosa of Patients With Irritable Bowel Syndrome. Gastroenterology, 2015, 148, 1002-1011.e4.	0.6	127
22	Chronic constipation in the elderly: a primer for the gastroenterologist. BMC Gastroenterology, 2015, 15, 130.	0.8	122
23	Functional variants in the sucraseâ€“isomaltase gene associate with increased risk of irritable bowel syndrome. Gut, 2018, 67, 263-270.	6.1	120
24	Chronic Intestinal Pseudo-Obstruction: Clinical Features, Diagnosis, and Therapy. Gastroenterology Clinics of North America, 2011, 40, 787-807.	1.0	118
25	Quantification and Potential Functions of Endogenous Agonists of Transient Receptor Potential Channels in Patients With Irritable Bowel Syndrome. Gastroenterology, 2015, 149, 433-444.e7.	0.6	116
26	Cross-cultural development and validation of a patient self-administered questionnaire to assess quality of life in upper gastrointestinal disorders: The PAGI-QOLï¿½. Quality of Life Research, 2004, 13, 1751-1762.	1.5	110
27	Mechanisms Underlying Visceral Hypersensitivity in Irritable Bowel Syndrome. Current Gastroenterology Reports, 2011, 13, 308-315.	1.1	109
28	Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier. Frontiers in Nutrition, 2021, 8, 718356.	1.6	98
29	Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. Gut, 2015, 64, 1774-1782.	6.1	97
30	Reversal of Fundic Atrophy After Eradication of Helicobacter pylori. American Journal of Gastroenterology, 1998, 93, 1425-1431.	0.2	95
31	Predominant Symptoms Identify Different Subgroups in Functional Dyspepsia. American Journal of Gastroenterology, 1999, 94, 2080-2085.	0.2	92
32	Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. American Journal of Gastroenterology, 2002, 97, 2454-2459.	0.2	91
33	Randomised controlled trial of mesalazine in IBS. Gut, 2016, 65, 82-90.	6.1	91
34	Gastrointestinal motility disturbances in patients with orthostatic hypotension. Gastroenterology, 1985, 88, 1852-1859.	0.6	86
35	Upper gastrointestinal motor activity in patients with slow-transit constipation. Digestive Diseases and Sciences, 1996, 41, 1999-2005.	1.1	83
36	Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. United European Gastroenterology Journal, 2017, 5, 773-788.	1.6	81

#	Article	IF	Citations
37	Dyspeptic symptoms and gastric emptying in the irritable bowel syndrome. American Journal of Gastroenterology, 2002, 97, 2738-2743.	0.2	79
38	Responsiveness and interpretation of a symptom severity index specific to upper gastrointestinal disorders. Clinical Gastroenterology and Hepatology, 2004, 2, 769-777.	2.4	79
39	Salmonella Gastroenteritis During Childhood Is a Risk Factor for Irritable Bowel Syndrome in Adulthood. Gastroenterology, 2014, 147, 69-77.	0.6	77
40	Effect of Lactobacillus paracasei CNCM Iâ€1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterology Journal, 2018, 6, 604-613.	1.6	77
41	Clinical and morphofunctional features of idiopathic myenteric ganglionitis underlying severe intestinal motor dysfunction: a study of three cases. American Journal of Gastroenterology, 2002, 97, 2454-2459.	0.2	76
42	Mutations in RAD21 Disrupt Regulation of APOB in Patients With Chronic Intestinal Pseudo-Obstruction. Gastroenterology, 2015, 148, 771-782.e11.	0.6	71
43	Features and Progression of Potential Celiac Disease in Adults. Clinical Gastroenterology and Hepatology, 2016, 14, 686-693.e1.	2.4	65
44	Esophageal and gastric nitric oxide synthesizing innervation in primary achalasia. American Journal of Gastroenterology, 1999, 94, 2357-2362.	0.2	62
45	A Mutation in Telethonin Alters Nav1.5 Function. Journal of Biological Chemistry, 2008, 283, 16537-16544.	1.6	59
46	Fecal Clostridiales distribution and shortâ€chain fatty acids reflect bowel habits in irritable bowel syndrome. Environmental Microbiology, 2018, 20, 3201-3213.	1.8	59
47	Constipation severity is associated with productivity losses and healthcare utilization in patients with chronic constipation. United European Gastroenterology Journal, 2014, 2, 138-147.	1.6	56
48	Audit of digestive complaints and psychopathological traits in patients with eating disorders: A prospective study. Digestive and Liver Disease, 2013, 45, 639-644.	0.4	55
49	Detection of substance P immunoreactivity in human peripheral leukocytes. Journal of Neuroimmunology, 1998, 82, 175-181.	1.1	54
50	Intestinal Transplantation for Chronic Intestinal Pseudo-Obstruction in Adult Patients. American Journal of Transplantation, 2004, 4, 826-829.	2.6	53
51	Inflammatory bowel disease and irritable bowel syndrome. Current Opinion in Gastroenterology, 2014, 30, 352-358.	1.0	53
52	Gastric secretion and emptying of liquids in reflux esophagitis. Digestive Diseases and Sciences, 1981, 26, 886-889.	1.1	52
53	One-day therapy for treatment ofHelicobacter pylori infection. Digestive Diseases and Sciences, 1993, 38, 1670-1673.	1.1	52
54	Idiopathic myenteric ganglionitis underlying intractable vomiting in a young adult. European Journal of Gastroenterology and Hepatology, 2000, 12, 613-616.	0.8	51

#	Article	IF	Citations
55	Serum zonulin and its diagnostic performance in non-coeliac gluten sensitivity. Gut, 2020, 69, 1966-1974.	6.1	49
56	Functional Dyspepsia and Irritable Bowel Syndrome: Beyond Rome IV. Digestive Diseases, 2017, 35, 14-17.	0.8	48
57	Responsiveness and interpretation of a quality of life questionnaire specific to upper gastrointestinal disorders. Clinical Gastroenterology and Hepatology, 2004, 2, 778-786.	2.4	45
58	Implications of SARSâ€CoVâ€2 infection for neurogastroenterology. Neurogastroenterology and Motility, 2021, 33, e14104.	1.6	45
59	12 Pseudo-obstruction syndromes. Bailliere's Clinical Gastroenterology, 1988, 2, 225-254.	0.9	44
60	Natural History of Intestinal Failure Induced by Chronic Idiopathic Intestinal Pseudo-Obstruction. Transplantation Proceedings, 2010, 42, 15-18.	0.3	44
61	Ambulatory intestinal manometry: a consensus report on its clinical role. Digestive Diseases and Sciences, 1997, 42, 2395-2400.	1.1	43
62	Variants of the ACTG2 gene correlate with degree of severity and presence of megacystis in chronic intestinal pseudo-obstruction. European Journal of Human Genetics, 2016, 24, 1211-1215.	1.4	43
63	Liver as a Source for Thymidine Phosphorylase Replacement in Mitochondrial Neurogastrointestinal Encephalomyopathy. PLoS ONE, 2014, 9, e96692.	1.1	42
64	1 Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: Clarifying the concepts. Bailliere's Clinical Gastroenterology, 1998, 12, 417-433.	0.9	41
65	GERD 2003 â€“ A Consensus on the Way Ahead. Digestion, 2003, 67, 111-117.	1.2	41
66	Interferon-Î³ is increased in the gut of patients with irritable bowel syndrome and modulates serotonin metabolism. American Journal of Physiology - Renal Physiology, 2016, 310, G439-G447.	1.6	40
67	Recent advances in understanding non-celiac gluten sensitivity. F1000Research, 2018, 7, 1631.	0.8	40
68	Does colorectal endometriosis alter intestinal functions? A prospective manometric and questionnaire-based study. Fertility and Sterility, 2012, 97, 652-656.	0.5	39
69	Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. American Journal of Gastroenterology, 2022, 117, 147-157.	0.2	39
70	New Developments in the Treatment of Functional Dyspepsia. Drugs, 2003, 63, 869-892.	4.9	37
71	Chronic intestinal pseudo-obstruction. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 657-669.	1.0	37
72	The Construction of a New Evaluative GERD Questionnaire â€“ Methods and State of the Art. Digestion, 2004, 70, 71-78.	1.2	36

#	Article	IF	Citations
73	Genetics of human enteric neuropathies. Progress in Neurobiology, 2012, 96, 176-189.	2.8	36
74	Prucalopride exerts neuroprotection in human enteric neurons. American Journal of Physiology - Renal Physiology, 2016, 310, G768-G775.	1.6	34
75	Is gastroparesis a gastric disease?. Neurogastroenterology and Motility, 2019, 31, e13562.	1.6	34
76	Non-Celiac Gluten Sensitivity in the Context of Functional Gastrointestinal Disorders. Nutrients, 2020, 12, 3735.	1.7	34
77	Dyspeptic symptoms in primary care. An observational study in general practice. European Journal of Gastroenterology and Hepatology, 2002, 14, 985-990.	0.8	32
78	Biomarkers in IBS: when will they replace symptoms for diagnosis and management?. Gut, 2009, 58, 1571-1575.	6.1	32
79	Contrast-Enhanced Ultrasound in the Differential Diagnosis of Exocrine Versus Neuroendocrine Pancreatic Tumors. Pancreas, 2013, 42, 871-877.	0.5	31
80	Gastrointestinal Bleeding in COVID-19 Patients: A Systematic Review with Meta-Analysis. Canadian Journal of Gastroenterology and Hepatology, 2021, 2021, 1-9.	0.8	30
81	Gastric emptying and dyspeptic symptoms in patients with nonautoimmune fundic atrophic gastritis. Digestive Diseases and Sciences, 2000, 45, 252-257.	1.1	29
82	A novel locus for syndromic chronic idiopathic intestinal pseudo-obstruction maps to chromosome 8q23â€“q24. European Journal of Human Genetics, 2007, 15, 889-897.	1.4	29
83	Acute abdominal pain in the emergency department of a university hospital in Italy. United European Gastroenterology Journal, 2016, 4, 297-304.	1.6	29
84	Determination of ReQuestâ„¢-Based Symptom Thresholds to Define Symptom Relief in GERD Clinical Studies. Digestion, 2005, 71, 145-151.	1.2	26
85	Allergic Proctocolitis Is a Risk Factor for Functional Gastrointestinal Disorders in Children. Journal of Pediatrics, 2018, 195, 128-133.e1.	0.9	26
86	Probiotics and Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2008, 42, S214-S217.	1.1	25
87	Âµâ€opioid receptor, Î²â€endorphin, and cannabinoid receptorâ€2 are increased in the colonic mucosa of irritable bowel syndrome patients. Neurogastroenterology and Motility, 2019, 31, e13688.	1.6	25
88	Aminosalicylates and Other Anti-Inflammatory Compounds for Irritable Bowel Syndrome. Digestive Diseases, 2009, 27, 115-121.	0.8	23
89	Transcriptional regulation of TLX2 and impaired intestinal innervation: possible role of the PHOX2A and PHOX2B genes. European Journal of Human Genetics, 2007, 15, 848-855.	1.4	22
90	Sympathetic hyperactivity in patients with ulcerative colitis. Clinical Autonomic Research, 2007, 17, 217-220.	1.4	22

#	Article	IF	Citations
91	Pain and Frailty in Hospitalized Older Adults. Pain and Therapy, 2020, 9, 727-740.	1.5	22
92	HOX11L1: a promoter study to evaluate possible expression defects in intestinal motility disorders. International Journal of Molecular Medicine, 2002, 10, 101-6.	1.8	22
93	Almost All Irritable Bowel Syndromes Are Post-Infectious and Respond to Probiotics: Controversial Issues. Digestive Diseases, 2007, 25, 245-248.	0.8	21
94	Neurogenic Chronic Intestinal Pseudo-Obstruction: Antineuronal Antibody-Mediated Activation of Autophagy Via Fas. Gastroenterology, 2008, 135, 601-609.	0.6	21
95	Mast cellâ€nerve interactions correlate with bloating and abdominal pain severity in patients with nonâ€celiac gluten / wheat sensitivity. Neurogastroenterology and Motility, 2020, 32, e13814.	1.6	21
96	Helicobacter pylori infection and gastric function in patients with fundic atrophic gastritis. Digestive Diseases and Sciences, 2001, 46, 1573-1583.	1.1	20
97	Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon?. Expert Review of Molecular Diagnostics, 2010, 10, 389-393.	1.5	19
98	Expression and regulation of Î±â€transducin in the pig gastrointestinal tract. Journal of Cellular and Molecular Medicine, 2013, 17, 466-474.	1.6	19
99	Clinical features of constipation in general practice in Italy. United European Gastroenterology Journal, 2014, 2, 232-238.	1.6	18
100	Risk indicators of organic diseases in uninvestigated dyspepsia. European Journal of Gastroenterology and Hepatology, 1999, 11, 1129-1134.	0.8	17
101	Gastric acid secretion and gastric emptying of liquids in 99 male duodenal ulcer patients. Digestive Diseases and Sciences, 1989, 34, 251-256.	1.1	16
102	A 5-Year Experience of Benign Pancreatic Hyperenzymemia. Pancreas, 2014, 43, 874-878.	0.5	15
103	Enteric neuron density correlates with clinical features of severe gut dysmotility. American Journal of Physiology - Renal Physiology, 2019, 317, G793-G801.	1.6	15
104	European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVIDâ€19 pandemic. Neurogastroenterology and Motility, 2020, 32, e13930.	1.6	15
105	Pathophysiology of Diverticular Disease: From Diverticula Formation to Symptom Generation. International Journal of Molecular Sciences, 2022, 23, 6698.	1.8	15
106	Nerve fiber overgrowth in patients with symptomatic diverticular disease. Neurogastroenterology and Motility, 2019, 31, e13575.	1.6	14
107	Delayed gastric emptying in functional dyspepsia. Current Treatment Options in Gastroenterology, 2004, 7, 259-264.	0.3	13
108	ReQuestâ„¢â€” the challenge of quantifying both esophageal and extra-esophageal manifestations of GERD. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 27-30.	1.0	12

#	Article	IF	Citations
109	Reduced Bcl-2 expression in the enteric nervous system (ENS) as a marker for neural degeneration in patients with gastrointestinal motor disorders (GIMD). Gastroenterology, 2000, 118, A867.	0.6	11
110	Pyridostigmine in Pediatric Intestinal Pseudo-obstruction: Case Report of a 2-year Old Girl and Literature Review. Journal of Neurogastroenterology and Motility, 2019, 25, 508-514.	0.8	11
111	Diagnostic challenges of symptomatic uncomplicated diverticular disease. Minerva Gastroenterology, 2017, 63, 119-129.	0.3	11
112	Unfulfilled Wishes by Gastric Electrical Stimulation. Clinical Gastroenterology and Hepatology, 2011, 9, 447-448.	2.4	10
113	Enteric neuropathology of congenital intestinal obstruction: A case report. World Journal of Gastroenterology, 2006, 12, 5229-33.	1.4	10
114	Overlap Between GERD and IBS. Journal of Clinical Gastroenterology, 2007, 41, S114-S117.	1.1	9
115	Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis. Expert Review of Gastroenterology and Hepatology, 2008, 2, 735-740.	1.4	9
116	Review article: adherence to Rome criteria in therapeutic trials in functional dyspepsia. Alimentary Pharmacology and Therapeutics, 2014, 40, 435-466.	1.9	9
117	Evidence of enteric angiopathy and neuromuscular hypoxia in patients with mitochondrial neurogastrointestinal encephalomyopathy. American Journal of Physiology - Renal Physiology, 2021, 320, G768-G779.	1.6	9
118	Determination of ReQuest^{TM}-Based Symptom Thresholds to Define Symptom Relief in GERD Clinical Studies. Digestion, 2007, 75, 55-61.	1.2	8
119	Sigmoid compliance and visceral perception in spinal cord injury patients. European Journal of Gastroenterology and Hepatology, 2012, 24, 340-345.	0.8	8
120	Pathophysiology and Clinical Management of Bile Acid Diarrhea. Journal of Clinical Medicine, 2022, 11, 3102.	1.0	8
121	Nickel sensitization in patients with gastroâ€esophageal reflux disease. United European Gastroenterology Journal, 2016, 4, 184-190.	1.6	7
122	Role of inflammation in pediatric irritable bowel syndrome. Neurogastroenterology and Motility, 2023, 35, e14365.	1.6	7
123	A Case of Paraneoplastic Inflammatory Neuropathy of the Gastrointestinal Tract Related to an Underlying Neuroblastoma: Successful Management With Immunosuppressive Therapy. Journal of Pediatric Gastroenterology and Nutrition, 2008, 46, 457-460.	0.9	6
124	Gut epithelial and vascular barrier abnormalities in patients with chronic intestinal pseudoâ€obstruction. Neurogastroenterology and Motility, 2019, 31, e13652.	1.6	6
125	Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry. Acta Diabetologica, 2021, 58, 1225-1236.	1.2	6
126	Feedback regulation and sensation. Digestive Diseases and Sciences, 1994, 39, 124S-127S.	1.1	5

#	Article	IF	Citations
127	Management of Dyspepsia in General Practice. Pharmacoeconomics, 1998, 14, 57-66.	1.7	5
128	The Rome II Criteria for Patients With Functional Gastroduodenal Disorders. Journal of Clinical Gastroenterology, 2003, 37, 92-93.	1.1	5
129	Benign Pancreatic Hyperenzymemia. Pancreas, 2017, 46, 5-7.	0.5	5
130	ReQuest: new dimensions in the assessment and management of GERD. Drugs of Today, 2005, 41 Suppl B, 7-11.	0.7	5
131	Asymptomatic Peptic Ulcer Disease. Drugs, 1991, 41, 821-824.	4.9	4
132	Autoimmune Hepatitis and Celiac Disease: Case Report Showing an Entero-Hepatic Link. Case Reports in Gastroenterology, 2010, 4, 469-475.	0.3	4
133	Fiber and macrogol in the therapy of chronic constipation. Minerva Gastroenterologica E Dietologica, 2013, 59, 217-30.	2.2	4
134	Effects of Acute Cold Pressor Test on Vagally Stimulated Gastric Acid Secretion and Circulating Levels of Human Pancreatic Polypeptide and Gastrin. Digestion, 1994, 55, 154-159.	1.2	3
135	Widespread Eradication of Helicobacter pylori: A Debate. Helicobacter, 1997, 2, 77-80.	1.6	3
136	Perspectives on irritable bowel syndrome: where have we been? Where are we now?. Expert Review of Gastroenterology and Hepatology, 2013, 7, 3-7.	1.4	3
137	Prokinetics in the treatment of acute intestinal pseudo-obstruction. IDrugs: the Investigational Drugs Journal, 2004, 7, 160-5.	0.7	3
138	Idiopathic dyspepsia. Current Treatment Options in Gastroenterology, 2005, 8, 175-183.	0.3	2
139	Detection of anticonductive tissue autoantibodies in a patient with chronic intestinal pseudo-obstruction and sick sinus syndrome. European Journal of Gastroenterology and Hepatology, 2013, 25, 1358-1363.	0.8	2
140	Tinnitus in patients on therapy with proton pump inhibitors (PPI) and in PPI non-users. Hearing, Balance and Communication, 2014, 12, 84-87.	0.1	2
141	Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. European Journal of Internal Medicine, 2019, 68, e7-e11.	1.0	2
142	Evaluation of gastrointestinal innervation in humans. Journal of the Autonomic Nervous System, 1993, 43, 5.	1.9	1
143	The stomach and obesity: the missing link, at last?. The Lancet Gastroenterology and Hepatology, 2017, 2, 842-843.	3.7	1
144	The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of the REPOSI registry. Age and Ageing, 2021, 50, 498-504.	0.7	1

#	Article	IF	Citations
145	Roundtable discussion: Differences between Japan and Western countries in the treatment of dyspepsia. Clinical Therapeutics, 1998, 20, D23-D32.	1.1	0
146	Neuroplasticity of the Enteric Nervous System Induced by Inflammatory Conditions of the Gut. Journal of Pediatric Gastroenterology and Nutrition, 2006, 43, S7-S8.	0.9	0
147	How Relevant Is Symptom Evaluation in NERD?. Digestion, 2008, 78, 11-16.	1.2	0
148	SeHCAT test for bile acid malabsorption: may â€œthe oldâ€•become â€œthe gold oneâ€•in the diagnostic burden of chronic diarrhea?. Clinical and Translational Imaging, 2021, 9, 177-180.	1.1	0
149	A mutation in telethonin alters Nav1.5 function. VOLUME 283 (2008) PAGES 16537-16544. Journal of Biological Chemistry, 2008, 283, 22336.	1.6	0